Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPRG.L Regulatory News (PRG)

  • There is currently no data for PRG

Non-Board Appointments

9 May 2005 07:01

Premier Research Group09 May 2005 For Immediate Release 9 May 2005 Premier Research appoints Anthony Orlando and Bruce C Stouch to New Senior Management Positions Premier Research Group plc (AIM: PRG) ("Premier Research", "Company" or "Group"), the international pharmaceutical services group today announces theappointment of -- Anthony Orlando, Ph.D and Bruce C Stouch Ph.D to seniormanagement positions in Premier Research. Dr Anthony Orlando, Ph.D has joined the US Operations of Premier Research Groupplc in the new position of Executive Director, Data Operations. Dr. Orlandobrings an exceptional background in Biostatistics and Data Management over thepast thirty years including key roles in pharmaceutical companies, the NationalCenter for Toxicological Research/FDA and at major contract researchorganizations. He most recently joined the company from his position as VicePresident, Biostatistics at SFBC New Drug Services. Dr. Orlando holds a Ph.D. inBiometry from Yale University, has co-authored many papers in his area ofexpertise and has supported several drug NDAs for a variety of indications. Hewill be responsible for US data management, programming and biostatistics forPremier Research. In addition to Dr. Orlando's position, Premier Research also is pleased toannounce that Bruce C. Stouch, Ph.D. has taken the international position ofChief Scientific Officer for the company. In Dr. Stouch's new role, he will leadthe company's efforts supporting expert FDA/statistical clinical design andanalysis capabilities. He will also establish and expand the company's newinitiative into Bayesian monitoring and analysis methods. Dr. Stouch has over15 years of biostatistics experience in pharmaceuticals. For 12 years, Dr. Stouch held position of Director of Biostatistics andScientific Data Management at Johnson & Johnson in Exton, PA, where he wasresponsible for strategic development and implementation of pharmacoeconomicmodels of emerging technologies in several therapeutic areas. Dr. Stouch hasbeen involved in over two dozen publications and acknowledgements. He holds anacademic appointment at the Philadelphia College of Medicine as Director,Biostatistics and Clinical Epidemiology. Dr. Stouch received his Ph.D. inBiostatistics and Epidemiology from Jefferson Medical College in 1997 through aprogram sponsored by Johnson & Johnson, and trained in post-graduate studiesfrom Temple University, Jefferson Medical College, and Harvard School of PublicHealth. Dr Simon Yaxley, CEO of Premier Research Group plc, commented: "We are proud andpleased to announce the significant strengthening of our data management andstatistics capabilities in the US Operations, we also believe that Tony andBruce place our company at the forefront of trial design, monitoring andanalysis methods worldwide." About Premier Research Premier Research Group plc is a contract research organisation focused on thedesign, management and reporting of all phases of clinical trials on behalf ofpharmaceutical and biotechnology companies. The Company specialises in oncology,central nervous system, paediatrics and anti-infectives. For Further information, please contact: Premier Research Group Plc Tel: 01344 458 311Dr Simon Yaxley, Chief Executive Buchanan Communications Tel: 020 7466 5000Lisa Baderoon/Diane Stewart/Rebecca Skye Dietrich This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Jul 201412:15 pmPRNResult of AGM
8th Jul 20147:00 amPRNAGM Statement
30th Jun 20144:02 pmPRNTotal Voting Rights
9th Jun 20147:00 amPRNIssue of Equity
5th Jun 20147:00 amPRNPositive Modelling Report - Lemphane Diamond Lesotho
3rd Jun 20144:40 pmRNSSecond Price Monitoring Extn
3rd Jun 20144:35 pmRNSPrice Monitoring Extension
23rd May 20149:34 amPRNNotice of AGM and Posting of Annual Accounts
23rd May 20147:00 amPRNAudited Final Results
19th May 20144:40 pmRNSSecond Price Monitoring Extn
19th May 20144:35 pmRNSPrice Monitoring Extension
12th May 20147:00 amPRNUpdate on Lemphane Kimberlite Project, Lesotho
7th Apr 20144:35 pmRNSPrice Monitoring Extension
3rd Apr 201410:15 amPRNUK Investor Show, London, 5 April 2014
26th Mar 20144:40 pmRNSSecond Price Monitoring Extn
26th Mar 20144:35 pmRNSPrice Monitoring Extension
24th Feb 20147:00 amPRNMining Lease finalised for Lemphane Kimberlite
19th Feb 201411:59 amPRNHolding(s) in Company
31st Jan 20143:04 pmPRNTotal Voting Rights
29th Jan 20147:00 amPRNDirectors' Shareholdings
13th Jan 20149:15 amPRNHolding(s) in Company
8th Jan 201411:34 amPRNResult of General Meeting
17th Dec 20137:27 amPRNAcquisition(s)
11th Dec 20137:00 amPRNOperational Update
10th Dec 20137:00 amRNSLemphane Kimberlite Tonnage Estimate Update
29th Nov 20132:18 pmPRNNotice of General Meeting
29th Nov 20137:00 amPRNTotal Voting Rights
25th Nov 20137:00 amPRNDirector Subscription
20th Nov 20137:00 amPRNHolding(s) in Company
15th Nov 20132:55 pmPRNSubscription
4th Nov 20137:00 amPRNNew Licence Award
21st Oct 20131:39 pmPRNHolding(s) in Company
16th Oct 20137:00 amPRNValuation of Diamonds
14th Oct 20137:00 amPRNAward of Mining Licence
19th Sep 20137:00 amPRNInterim Results
31st Jul 201312:09 pmPRNTotal Voting Rights
18th Jul 201311:35 amPRNIssue of Equity
18th Jul 201311:20 amPRNResult of AGM
17th Jul 20137:04 amPRNOperational Update
8th Jul 201312:01 pmPRNIssue of Options
21st Jun 20137:00 amPRNHolding(s) in Company
14th Jun 20137:25 amPRNNotice of Results and AGM
11th Jun 20134:08 pmPRNHolding(s) in Company
7th Jun 20132:52 pmPRNHolding(s) in Company
29th May 20137:02 amPRNSubscription to raise £1.55 million
29th May 20137:01 amPRNPreliminary Results
29th May 20137:00 amPRNAppointment of Nomad & Broker
29th Apr 20137:00 amRNSLemphane Bulk Sampling Program Update
22nd Apr 20133:40 pmRNSAppointment of joint broker
22nd Apr 20137:00 amRNSLemphane Scoping Study Released

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.